[Direct gallstone dissolution therapy with GS-100].
We have developed GS-100, a new direct dissolving drug with strong dissolution property for cholesterol stone by supplementing d-limonene, a dissolvent used since 1974, with 30% medium-chain monoglyceride (MCM). The new drug was applied in 23 patients with gallbladder stones and three with bile duct stone. The presumptive analysis of the composition of the stones was drawn from the CT recordings. As non-invasive therapies, methyl tert-butyl ether (MTBE) dissolution and extracorporeal shock wave lithotripsy (ESWL), which are commonly used in Europe and America, have been reported as being favourable; however, GS-100 is superior in respect to safety and applicative dimension, suggesting of the possibility of using GS-100 as an important drug in the non-invasive therapy for gallstone in the near future.
Yamamoto
F
F
Yamamoto Surgical Hospital.
Igimi
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002769:Cholelithiasis / Q000188:drug therapy* / Q000517:prevention & control; D000081005:Cyclohexane Monoterpenes; D004338:Drug Combinations; D004987:Ethers / Q000627:therapeutic use; D005260:Female; D005989:Glycerides / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008738:Methyl Ethers; D008875:Middle Aged; D039821:Monoterpenes; D012008:Recurrence; D013729:Terpenes / Q000627:therapeutic use*
D000081005:Cyclohexane Monoterpenes; D004338:Drug Combinations; D004987:Ethers; D005989:Glycerides; D008738:Methyl Ethers; D039821:Monoterpenes; D013729:Terpenes; C083055:d-limonene-medium-chain monoglyceride; C043243:methyl tert-butyl ether